MedTrace Logo

Study of BC3195 Monotherapy in Patients With Advanced Solid Tumors

NCT05957471 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2023-07-24

No results posted yet for this study

Summary

This is a phase I study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Efficacy of BC3195 in Patients with Locally Advanced or Metastatic Solid Tumors.

Conditions

  • Locally Advanced or Metastatic Solid Tumors

Interventions

DRUG

Drug: BC3195 for Injection

BC3195 via intravenous(IV).

Sponsors & Collaborators

  • Biocity Biopharmaceutics Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-26
Primary Completion
2025-06-30
Completion
2025-06-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05957471 on ClinicalTrials.gov